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Abstract: Bronchopulmonary dysplasia, or BPD, is a chronic pulmonary disorder of premature infants, commonly deﬁ  ned 
as having an oxygen requirement at 36 weeks postmenstrual age. It is an important source of morbidity and mortality in 
premature neonates. Its’ etiology appears to be multifactorial with the most common associations being prematurity, need 
for mechanical ventilation, and oxygen exposure. Implied in the pathogenesis of BPD is the role of cytokines which are 
immune mediators produced by most cell types. This is evidenced by studies in which there exist alterations in the levels 
of “pro-inﬂ  ammatory” and “anti-inﬂ  ammatory” cytokines. The imbalance of these cytokines have either heralded the onset 
or predicted the presence of BPD, or indicated a decreased propensity to developing this chronic respiratory disorder of 
preterm infants. Many other pulmonary markers have been shown to be altered in patients with BPD. These include mark-
ers indicative of altered lung repair processes, decreased endothelial integrity, oxidative damage and abnormal ﬁ  brinolytic 
activity, all of which are thought to be mechanisms contributing to the development of BPD.
In this review, we will discuss the physiologic role of speciﬁ  c biomarkers in the pulmonary tract of the human premature 
neonate, the perturbations that enable them to be deranged, and their proposed association with BPD.
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Introduction
Bronchopulmonary dysplasia, or BPD, is a chronic pulmonary disorder of premature infants and is com-
monly deﬁ  ned as having an oxygen requirement at 36 weeks postmenstrual age. It is an important source 
of morbidity and mortality in premature neonates. Overall, 30% of premature neonates with a birth weight 
less than 1500 grams are affected, but the majority of these are neonates with a birth weight of 
501–750 grams, who have BPD at a rate of 52%. The multifactorial etiology of BPD includes genetic 
predisposition, baro-trauma and volu-trauma from mechanical ventilation in surfactant-deﬁ  cient premature 
lungs, reactive oxygen species from prolonged oxygen use and high oxygen concentrations, pre- and 
postnatal infections, and presence of a patent ductus arteriosus (PDA) with its’ resultant pulmonary over-
circulation.(1, 2) The aforementioned factors and the relatively poor, early postnatal nutrition of prema-
ture infants promote abnormal postnatal development of the immature lung. These factors contribute to 
inﬂ  ammation, damage, attenuated repair and growth of gas-exchanging surfaces, leading to the clinical 
manifestations inherent to BPD.
Cytokines are immune mediators produced by a variety of cell types, and have been implicated in 
the pathogenesis of BPD. This is evidenced by studies in which there exist alterations in the levels of 
“pro-inﬂ  ammatory” and “anti-inﬂ  ammatory” cytokines. The imbalance of these cytokines have heralded 
the onset, predicted the presence of BPD, or indicated a decreased propensity to developing this chronic 
respiratory disorder of preterm infants. Other biomarkers measured in tracheal ﬂ  uid have been altered 
in patients at risk for, or diagnosed with BPD. These include markers indicative of altered lung repair 
processes, decreased endothelial integrity, oxidative damage and decreased ﬁ  brinolytic activity, all 
factors potentially contributing to the pathogenesis of BPD.
Lung Development
Intrinsic to the development of BPD is prematurity. Normal lung development occurs in phases which 
correspond to structural differences. The ﬁ  rst phase, the embryonic phase, occurs at 3–7 weeks 
post-menstrually. The pseudoglandular phase occurs next, from 5–17 weeks. At 16–26 weeks 362
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postmenstrual age, the cannalicular phase occurs. 
Many premature neonates may be born during this 
phase of lung development. The saccular phase 
occurs at 24–38 weeks and accounts for the time 
when the majority of patients who develop BPD 
are born. The last phase, the alveolar phase, occurs 
from about 32 weeks postmenstrual age, till about 
18 months after birth, with the majority of the 
alveolarization process occurring 5–6 months after 
birth.(3) Intrinsic to the process of normal lung 
development is alveolarization, which incorporates 
the processes of “elastogenesis and angiogenesis,” 
with multiple cell to cell interactions between 
epithelial cells (type 1 and 2 pneumocytes), 
ﬁ  broblasts, interstitial cells and endothelial cells.(4) 
Premature birth, with its subsequent medical 
disorders and their management, alters the 
postnatal development of these very premature 
lungs, via changes in the usual signaling pathways. 
Factors that disrupt normal angiogenesis, control 
of inﬂ  ammation (i.e. imbalance between “pro”- and 
“anti-inﬂ  ammatory” cytokines), and appropriate 
fibrin depostion or removal are at play in the 
pathogenesis of BPD. Many of the pulmonary 
biomarkers that have been studied relate to the 
possible disruption in the above mechanisms.
Pathophysiology of BPD
Clinical manifestations and treatment
Clinically, BPD presents as continued oxygen 
dependence, observed as a premature infant 
approaches 36 weeks postmenstrual age. The 
pharmacologic armamentarium may include 
diuretics, postnatal steroids and caffeine. 
Occasionally beta-2 agonists, inhaled anticholin-
ergics and vitamin A are used.(1) Other strategies 
include ﬂ  uid restriction, adequate caloric intake to 
enhance growth and healing, and gentle ventilatory 
support as needed.
Radiographic and pathologic ﬁ  ndings
Recently there has been a change in the radio-
graphic and pathologic ﬁ  ndings associated with 
BPD. This change has likely been brought about 
by the younger gestational age of surviving infants, 
widespread use of surfactant, and less aggressive 
respiratory management strategies. The result has 
been a change in the architectural aberrations that 
are noted in the lungs of premature neonates with 
BPD. Traditionally, in the pre-surfactant era, BPD 
or chronic lung disease of prematurity, was 
represented on radiographic imaging by emphyse-
matous areas with other portions of the lung 
displaying volume loss. Pathologically, pulmonary 
specimen would also exhibit signs of increased 
inﬂ  ammation, ﬁ  brosis and small airway disease. 
Pathologic ﬁ  ndings of more recent BPD include 
impaired alveolar and pulmonary vascular 
development, with dilated alveolar spaces, and 
minimal alveolar ﬁ  brosis and inﬂ  ammation when 
compared to the older form of BPD. Radiograph-
ically, the lungs initially appear hazy, dense, and 
progress to hyperinﬂ  ation, but without the large 
cysts typical of the older form of BPD.(2, 5, 6)
Role of cytokines
Cytokines are chemicals produced by virtually all 
cell types including white blood cells, endothelial 
and epithelial cells, ﬁ  broblasts and type II pneumo-
cytes. They mediate immune, inﬂ  ammatory and 
hematopoietic functions in response to various 
stimuli.(7) In preterm infants, inciting events cause 
an inﬂ  ammatory response, either systemically or 
localized to the pulmonary organ. We have only a 
partial understanding of how inﬂ  ammation in the 
setting of prematurity causes BPD. It likely results 
from an imbalance of  “pro”- and “anti-inﬂ  ammatory” 
factors. Soon after birth, upon initiation of 
mechanical ventilation, there is an influx of 
neutrophils and macrophages into pulmonary inter-
stitium. Neutrophils adhere to the endothelium, with 
interaction between these two cell types occurring 
via adhesion molecules (e.g. selectins and integrins). 
This allows for extravasation of neutrophils and 
macrophages towards the speciﬁ  c areas of injury. 
These inﬂ  ammatory cells produce cytokines and 
other signaling molecules for augmentation of the 
inﬂ  ammatory response in an attempt to mitigate the 
damage of the inciting insult. There is subsequent 
disruption of the alveolar capillary unit and pulmo-
nary tissue integrity. The imperfect attempt at 
repair, differentiation and growth of these tissues 
act in concert with the inﬂ  ammation to produce the 
biochemical proﬁ  le, signs and symptoms we see in 
patients with, and those at risk, for BPD.(2, 3, 8, 9) 
Many studies have been conducted to evaluate the 
presence of cytokines in the amniotic ﬂ  uid, cord 
blood, plasma and tracheal secretions of preterm 
neonates at risk or who have BPD in an effort to 
determine a biochemical proﬁ  le of the condition.363
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Proposed mechanisms
Genetic predisposition, baro-trauma and 
volu-trauma from mechanical ventilation in 
surfactant-deficient premature lungs, reactive 
oxygen species from prolonged oxygen use and 
high oxygen concentrations, pre- and postnatal 
infections, and presence of a PDA have all been 
factors associated with the development of 
BPD.(1, 5, 9, 10) See Figures 1 and 2.
Genetics
In a paper published in 2006, Bhandari and 
colleagues explored the genetic basis for conditions 
common to very premature infants. BPD and its’ 
potential for genetic predisposition was assessed. 
It was observed that in premature twins 
(63 monozygotic and 189 dizygotic twin pairs), 
less than 32 weeks gestational age, BPD occurred 
at a rate of 29% in one or more of a twin pair. After 
controlling for other covariates, 53% (p = 0.004) 
of BPD was explained by genetic factors alone.(11) 
Multiple genetic variants have been assessed in the 
evaluation of carrier states that predispose to the 
development of BPD. The interested reader is 
directed toward a recent review of this topic for 
more detailed information.(12)
Prenatal infections
Chorioamnionitis may be a risk factor for the 
development of BPD. Though the pathogenesis 
is incompletely understood, multiple studies 
have studied the cytokine presence in the amni-
otic ﬂ  uid of infants born prematurely, for reasons 
which may include chorioamnionitis. Some 
studies have indicated increased levels of cyto-
kines, predominantly interleukins (IL), IL-1β, 
IL-6, IL-8, and many of these patients go on to 
develop BPD.
Though there is difﬁ  culty in correlating clini-
cal and histologic chorioamnionitis, it has been 
shown that those infants who are born prema-
turely before 28 weeks postmenstrual age have 
BRONCHOPULMONARY DYSPLASIA
Infections
(pre/postnatal)
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predisposition
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or Saccular 
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Development
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Baro/volutrauma 
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Figure 1. Multifactorial etiology of Bronchopulmonary Dysplasia.364
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evidence of histologic chorioamnionitis, and 
have worse pulmonary outcomes at a higher 
rate than those born at later gestational ages. 
They also had more elevated levels of inflam-
matory cytokines in their blood.(13) Watterberg 
and colleagues have reported that infants 
exposed to intrauterine inflammation have 
decreased rates of respiratory distress syndrome 
(RDS); however, they had no decrease in rates 
of BPD.(14) Other authors have explored the 
relationship between chorioamnionitis and 
BPD and have indicated that in-utero exposure 
to low level inflammation may induce a 
pulmonary maturation, possibly leading to 
decreased rates of BPD.(10) Van Marter and 
colleagues found that antenatal infection, 
coupled with postnatal sepsis, and mechanical 
ventilation increased the rates of BPD in 
preterm neonates.(15)
Postnatal infections
Systemic infections such as sepsis, necrotizing 
enterocolitis, etc., predispose to the development 
of BPD. The inﬂ  ammatory response occurring 
secondary to infection, increases release of 
inflammatory and vasoactive cytokines on an 
already damaged pulmonary organ, increasing the 
need for mechanical ventilation. Airway coloniza-
tion, with increased neutrophilic presence and 
“pro-inﬂ  ammatory” cytokines may also predispose 
to the development of BPD.(2) Other studies have 
indicated a predisposition to BPD in neonates with 
postnatal infections.(15)
Baro- and Volutrauma
Mechanical ventilation has long been associated 
with the development of BPD. Intubated neonates 
who ultimately develop BPD often have signiﬁ  -
cantly increased levels of “pro-inflammatory” 
cytokines, possibly from microbial colonization 
and increased distention of alveolar tissue with 
subsequent baro- and volutrauma leading to 
increased inﬂ  ammation.(2, 3, 5, 16)
The association of presence of a PDA and BPD 
is observed likely due to the increase in pulmonary 
circulation and subsequent need for ventilatory 
support and oxygen administration, factors leading 
to BPD development.
Hyperoxia
Excessive oxygen induces oxidative stress with 
production of reactive oxygen species which 
directly damages respiratory epithelium by inducing 
necrosis and/or apoptosis, subsequently increasing 
production of inﬂ  ammatory cytokines.(17, 18) 
Initial hyperoxic cellular damage induces alveolar 
or interstitial macrophages to express early cyto-
kines such as IL-1 and tumor necrosis factor (TNF). 
Chemoattractants are then induced from multiple 
cell types in the lung, in turn recruiting other inﬂ  am-
matory cells, such as neutrophils.(18)
Late 
Canalicular/Saccular 
Lung Phase
Disrupted 
pulmonary 
Angiogenesis
Abnormal remodeling 
with ↑ fibrin deposition 
and ↓ fibrin degradation 
Cytokine  release from 
damaged pulmonary 
epithelium → Influx of 
inflammatory cells→↑
cytokine release
Hyperoxia
↓
Reactive Oxygen 
Species damage 
pulmonary tissues
Abnormal alveolar  
septation, growth, repair
Figure 2. Sources of pulmonary biomarkers of Bronchopulmonary Dysplasia.365
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Source of Biomarkers in BPD
Though the biomarkers indicating a likelihood of 
developing BPD may be measured in serum, our 
interest lay in studies that assessed their pulmonary 
concentrations speciﬁ  cally. It was felt that this 
would give a more precise representation of the 
pathological processes speciﬁ  c to the lung and 
decrease the possibility that altered levels of bio-
markers existed only because there was systemic 
pathology, or that which involved another organ. 
Bronchoalveolar lavage is one such procedure that 
may yield accurate information, but is deemed 
more invasive than performing tracheal aspirates. 
In addition, D’Angio and colleagues have shown 
that tracheal aspirates when done under standard-
ized technique in neonates can be a suitable 
alternative to bronchoalveolar lavage in most cir-
cumstances.(19) One could postulate that these 
methods of sampling may be more representative 
of responses more proximal in the respiratory tract 
and not accurately reﬂ  ect the processes present in 
the human premature lung that indicate or predis-
pose to BPD. However, the routine and relatively 
standardized performance of obtaining tracheal 
aspirates from intubated neonates makes it an 
accessible option for the evaluation of pulmonary 
biomarkers. Hence, the majority of the pulmonary 
biomarkers to be discussed in the next section have 
been measured in tracheal aspirates.
Pulmonary Biomarkers in BPD
Though there are many clinical associations indica-
tive of an increased risk for the eventual develop-
ment of BPD, currently there exists no one factor 
or marker that uniformly and accurately predicts its 
development. We are limited to waiting for oxygen 
dependence at 36 weeks postmenstrual age to deter-
mine its’ presence. The inciting events that predis-
pose to development of BPD likely occur fairly soon 
after birth, and we are limited by a lack of ability to 
distinguish very early on, those neonates who will 
likely go on to develop this chronic disorder. All the 
biomarkers below are likely abnormal due to dam-
age that has already occurred. See Figure 3.
Some biomarkers are capable of being 
perceived as either “pro-inflammatory” or 
anti-inﬂ  ammatory,” depending on their concentration 
relative to their physiologic role.
Categories of pulmonary biomarkers that are 
deranged in BPD are interleukins and other 
chemo-attractant molecules, markers indicative of 
abnormal angiogenesis, those signifying abnormal 
fibrin deposition or degradation, markers of 
oxidative damage, and peptide growth factors. 
These have been summarized in Table 1.
Interleukins (IL)
Interleukins are chemicals made by one cell type 
that act on other inﬂ  ammatory cells. They may 
induce growth, differentiation and proliferation of 
other leukocytes. They may also act as chemo-
attractants for recruitment of other cell types 
(immune and non-immune cells) to a site of injury, 
and may exert pro- or anti-inﬂ  ammatory effects.
IL-1β, 6, 8, 16
IL-1β and 6 are particularly active in the acute 
phase response to injury, while IL-8 is a potent 
chemotactic agent for recruitment of neutrophils. 
Typically viewed as proinﬂ  ammatory, these cyto-
kines have been shown to be elevated very early 
in the respiratory course of the preterm population 
that ultimately develops BPD, and in those with 
BPD at the time their tracheal aspirates are 
assessed. These ﬁ  ndings have been replicated in 
multiple studies.(20–27)
IL-16 acts as a chemoattractant for CD4+ T 
lymphocytes, monocytes and eosinophils. In a 
study to correlate levels of pro-inﬂ  ammatory cyto-
kine IL-16 and its’ relation to BPD, Wang and 
colleagues, enrolled 34 intubated infants, 27 of 
whom were preterm. BPD developed in 11 of the 
preterm infants, with 6 of the 11 infants having 
detectable IL-16 levels, i.e. 16 of 46 tracheal aspi-
rate samples. This was compared to 1 of 30 tracheal 
samples from non-BPD patients positive for IL-16, 
p = 0.001. Levels of IL-16 also correlated 
signiﬁ  cantly with neutrophil counts in the tracheal 
aspirates.(28)
IL-10, 4, 13
These cytokines usually act in an anti-inﬂ  ammatory 
capacity, and are responsible for the production, 
differentiation and proliferation of B cells and 
macrophages. One could hypothesize that 
decreased levels of  “anti-inﬂ  ammatory” cytokines 
would predispose to the development of BPD given 
the role that inﬂ  ammation likely has in this disor-
der. However, there are discrepant ﬁ  ndings regard-
ing the levels of “anti-inﬂ  ammatory” cytokines in 
the tracheal ﬂ  uid of preterm infants at risk for BPD, 
particularly IL-10, seemingly the most studied.366
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IL-10
In Vento and colleagues’ study to assess the levels 
of seven cytokines and their association with the 
development of BPD, it was found that IL-10 was 
decreased in those infants who developed the dis-
order, on days 1, 3 and 5.(22) Oie, et al.’s study in 
48 preterm infants, with tracheal aspirate samples 
taken in the ﬁ  rst seven days of life, also conﬁ  rmed 
this ﬁ  nding.(29) McColm and colleagues found 
detectable levels of IL-10 in tracheal aspirates of 
preterm ventilated infants, but could not correlate 
the levels with development of BPD.(30) Garingo 
and colleagues, attempted to induce production of 
IL-10 from lung inﬂ  ammatory cells (obtained from 
infants, 33/37 who were premature), with lipopoly-
saccharide (LPS), a potent inducer of inﬂ  ammation. 
Their results indicated a decreased ability to induce 
IL-10 in those infants who went on to develop BPD; 
i.e. 97% of the preterm infants unable to constitu-
tively express the IL-10 gene developed BPD.(31)
IL-4, 13
IL-4 is produced by T lymphocytes and alveolar 
macrophages, and induces cytokines, some “pro-
inﬂ  ammatory” and others “anti-inﬂ  ammatory”. 
However, they are typically felt to be mostly anti-
inﬂ  ammatory in their actions. Overall, in a study 
by Baier and colleagues to assess levels of IL-4 
and IL-13, it was found that levels of these poten-
tially “anti-inﬂ  ammatory” cytokines could not be 
signiﬁ  cantly correlated with the development of 
BPD.(32)
Angiopoietin-2
Angiopoietin-2 is an angiogenic growth factor that 
destabilizes blood vessels, enhances vascular leak 
and induces endothelial cell necrosis in hyperoxic 
conditions. Its’ concentration was observed to be 
increased in infants with BPD and/or death, when 
compared to those infants with RDS who 
recovered.(17, 33)
↑Malondialdehyde
↓Lactoferrin   
Ongoing Cellular and Oxidative damage 
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Figure 3. Proposed sequence of events eliciting alterations in the pulmonary biomarkers observed in Bronchopulmonary Dysplasia (see 
text for abbreviations).367
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Cathepsin K
Cathepsin K is a cysteine protease, which degrades 
existing extracelluar matrix and regulates the release 
of matrix proteins from ﬁ  broblasts. In one study, 13 
intubated patients with 46 tracheal aspirates were 
evaluated. Six of 13 infants developed BPD, and 
had declining cathepsin K levels by day13, when 
compared to neonates who did not.(34)
CC Chemokines
There are 4 families of chemokines (chemotactic 
cytokines); they play a role in regulating inﬂ  ammation 
by recruiting inﬂ  ammatory cells to the area of injury. 
The ‘CC’ family consists of monocyte chemoattractant 
proteins (MCP) 1, 1α, 1β, 2 and 3. These chemokines 
were measured in a study to assess the role of CC 
chemokines in acute lung injury in the preterm, 
Table1. Pulmonary biomarkers, proposed physiologic roles and alteration in BPD.
Biomarker Physiologic role Level in BPD
Interleukins: Proinﬂ  ammatory
IL-1β, IL-6, IL-16 Acute phase response ↑
IL-8/CXCL-8 Potent chemotactic agent for neutrophil recruitment ↑
Interleukins: anti-inﬂ  ammatory
IL10 Above + inhibits transcription factor NF-κβ which 
limits the inﬂ  ammatory response
↓/↔
IL-4, IL-13 Production, differentiation and proliferation
of B cells and macrophages. Also inhibits 
proinﬂ  ammatory cytokine production
↔
Angiopoietin-2 Angiogenesis ↑
Cathepsin K Protease ↓
CC Chemokines: MCP-1,
1α, 1β, 2 and 3
Inﬂ  ammatory mediator ↑
Clara Cell Secretory Protein Immunomodulator ↓
3-Chlorotyrosine Marker of neutophil oxidation ↑
Fibronectin Extracellular matrix formation ↑
Lysozyme Bacteriocidal ↓
Lactoferrin Antioxidant/anti-inﬂ  ammatory ↓
Macrophage migration inhibitory factor Inﬂ  ammatory mediator ↓
Malondialdehyde Oxidative byproduct ↑
Matrix Metalloproteinase-8 Protease (remodeling) ↑
NF-κβ Transcription factor activated by signs of cellular 
stress
↑
Parathyroid Hormone-Related Protein Alveolar growth/development ↓
Plasminogen Activator Inhibitor Fibrinolysis ↑
Pulmonary Trypsin-2 Protease ↑
Soluble ICAM Intercellular adhesion molecule for inﬂ  ammatory, 
endothelial and bronchial epithelial cells
↑
Transforming Growth Factor- β1 Proﬁ  brotic ↑
Tumor Necrosis Factor –ά Induces cell death, and enhances expression
of other cytokines
↑
Peptide Growth Factors
Endothelin-1 Vaso/bronchoconstrictor, proinﬂ  ammatory ↑
Fibroblast Growth Factor-2 Angiogenic, endoproliferative ↑
Keratinocyte Growth Factor Alveolar epithelial proliferation, repair ↓
Pulmonary Hepatocyte Growth Factor Alveolar septation, maintenance, repair ↓
Vascular Endothelial Growth Factor Angiogenesis ↑/↓368
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ventilated infant over the ﬁ  rst 21 days of life. Fifty-six 
very low birth weight infants were enrolled, and the 
above chemokines were measured. Fourteen infants 
developed BPD. MCP- 1, 1α, 1β, 2 and 3 were all 
increased in those infants developing BPD. However, 
only MCP- 1, 2 and 3 were statistically signiﬁ  cant, 
with MCP-3 being the most signiﬁ  cant.(35)
Clara cell secretory protein (CCSP)
CCSP is produced by Clara cells, which are 
non-ciliated epithelial cells lining the respiratory 
and terminal bronchioles. It is hypothesized that 
this protein may act to modulate acute pulmonary 
inﬂ  ammatory processes. In 24 preterm infants 
with 98 tracheal aspirate samples taken up to 2 
weeks after birth, it was noted that Clara cell 
secretory protein increased with maturity, and was 
increased in those neonates who had evidence of 
infection.(36) In another study by Ramsay and 
colleagues, they enrolled 45 preterm neonates, 
with 19 developing BPD. Their hypothesis was 
that oxidation of proteins important to pulmonary 
function occurred and predisposed preterm infants 
to BPD. Overall their results indicated that lower 
levels of CCSP predisposed to development of 
BPD.(37)
3-Chlorotyrosine
3-Chlorotyrosine is a biomarker of the neutrophil 
oxidant, hypochlorous acid, used in the inﬂ  ammatory 
process. Its’ only source is from neutrophils and 
monocytes which release myeloperoxidase to 
catalyze oxidation of chloride by hydrogen 
peroxide to give hypochlorous acid. In support of 
data that neutrophilic inﬁ  ltration and subsequent 
oxidative injury is closely related to the develop-
ment of BPD, Buss and colleagues assessed levels 
of 3-chlorotyrosine, and found that an increase in 
their concentration correlated with development 
of BPD.(38)
Fibronectin
An extracellular matrix component, ﬁ  bronectin is 
important in maintaining the integrity of pulmonary 
tissues and microvasculature. Watts and colleagues 
enrolled 32 infants in a study to assess ﬁ  bronectin 
levels in those infants developing BPD. Eighteen 
out of 32 developed BPD. Their results indicate a 
higher ﬁ  bronectin level in those infants developing 
BPD.(39)
Lactoferrin and Lysozyme
Lactoferrin is hypothesized to be a marker of 
inﬂ  ammation by regulating granulocyte and mac-
rophage proliferation, and may also have some 
antioxidant properties. Lysozyme is a bactericidal 
protein that degrades the walls of susceptible 
bacteria. Both are hypothesized to be released 
from the serous cells of the submucous glands of 
the respiratory tract. Revenis and colleagues stud-
ied 36 preterm patients, of which 18 developed 
BPD. It was hypothesized that the levels of 
neutrophil-derived lactoferrin and lysozyme 
would be increased in the airway ﬂ  uid from babies 
“predisposed” to the development of BPD. Both 
lactoferrin and lysozyme when measured in the 
ﬁ  rst 3 days of life were decreased in those patients 
with BPD as compared to those who did not have 
BPD, with the decrease in lysozyme being 
signiﬁ  cant.(40)
Macrophage migration inhibitory 
factor (MIF)
MIF is an upstream regulator of the innate immune 
response. It has been implicated in the pathogenesis 
of a number of inﬂ  ammatory disorders including 
sepsis, acute respiratory distress syndrome (in 
adults), asthma, and inflammatory/autoimmune 
diseases. MIF was quantiﬁ  ed in tracheal aspirates 
obtained during the ﬁ  rst 2 days of life in a cohort of 
26 neonates with RDS. There was a reduction in the 
concentration of MIF in the lungs of those infants 
with RDS who went on to develop BPD.(41)
Malondialdehyde
Malondialdehyde is a marker of oxidative damage, 
possibly from oxygen radicals produced under 
hyperoxic conditions, or the respiratory burst from 
inﬂ  ammatory cells present in the pulmonary organ. 
In one study of 43 preterm ventilated infants, its’ 
pulmonary concentrations were noted to be 
elevated. However, this elevation in the concentration 
of malondialdehyde was only weakly correlated 
with the development of BPD.(42)
Matrix metalloproteinase-8 (MMP-8)
Matrix metalloproteinases are a family of 
endoproteinases that aid in the remodeling and 
degradation of extracellular matrix and basement 
membranes. They are secreted in inactive form, 
activated in extracellular spaces and cell surfaces 369
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by oxidants and serine proteinases. They also have 
the capacity to activate each other. The development 
of BPD is partially characterized by disordered 
pulmonary repair after inﬂ  ammation. Cederqvist, 
et al. found that patients who went on to develop 
BPD had increased levels of tracheal MMP-8, with 
decreased levels of its’ inhibitor ‘tissue inhibitor 
of metalloproteinases’ (TIMP).(43)
Nuclear factor- kappa B (NF-κβ)
NF-κß is a transcription factor activated by signs 
of cellular stress, subsequently promoting expression 
of multiple genes including pro-inflammatory 
cytokines. Tracheal aspirates of thirty-three 
preterm infants were assessed several times over 
the ﬁ  rst 2 weeks of life, for correlation between 
NF-κβ levels and development of BPD. Levels of 
this biomarker were signiﬁ  cantly elevated in the 
infants who developed BPD or died.(44)
Parathyroid hormone-related protein 
(PTHrP)
PTHrP is secreted by type II pneumocytes and 
plays a role in the normal alveolar growth and 
development. It’s signaling was shown to be down-
regulated in alveolar over-distention and under 
hypoxic conditions.(45, 46) It was then thought 
that PTHrP levels would correlate with development 
of BPD. In 2006, Rehan and colleagues, studied 
this by enrolling 40 VLBW infants; 12 of 40 
developed BPD, and had signiﬁ  cantly lower levels 
of PTHrP in the ﬁ  rst week of life, when compared 
to those who did not.(47)
Plasminogen activator inhibitor-1 
(PAI-1)
PAI-1 is a regulator of fibrinolysis. It was 
hypothesized that inhibition of ﬁ  brinolysis may 
play a role in the development of  BPD. Thirty-seven 
intubated, preterm infants were enrolled and 
tracheal aspirates taken in the ﬁ  rst two weeks of 
life. Fifteen infants developed BPD with signiﬁ  -
cantly higher levels of PAI-1 than non-BPD 
patients.(48)
Pulmonary trypsin-2
Trypsin-2 is a serine protease expressed in a variety 
of human epithelial cell types, including the lung. 
It can directly attack extracellular protein matrix, 
basement membrane proteins, and can activate 
matrix metalloproteinases (MMPs) and initiate 
protease cascades, causing tissue destruction. It 
was hypothesized by Cederqvist and colleagues 
that when trypsin is ineffectively inhibited by its’ 
natural inhibitor tumor-associated trypsin inhibitor 
(TATI), it may play a role in the development of 
BPD. Thirty-nine infants were studied in the ﬁ  rst 
2 weeks of life, yielding 249 tracheal aspirate 
samples for evaluation. Results indicated that there 
was signiﬁ  cantly higher trypsin-2 to TATI ratio 
during weeks one and two in those infants 
developing BPD.(49)
Soluble intercellular adhesion 
molecule-1 (ICAM-1)
Intercellular adhesion molecule-1 plays a role in 
early inﬂ  ammation and is the ligand for lymphocyte 
function-associated antigen 1 (LFA-1). ICAM-1 is 
expressed by mast cells, lymphocytes, eosinophils, 
endothelial and bronchial epithelial cells. Tracheal 
aspirates from 15 premature neonates were 
analyzed for soluble ICAM-1 content and evalu-
ated for the relation to the development of BPD. 
Nine infants developed BPD, and it was found that 
these patients had signiﬁ  cantly higher levels of 
soluble ICAM-1 at 6–14 days of age.(50)
Transforming growth factor–β1 
(TGF–β1)
TGF–β1 is produced mostly by alveolar 
macrophages, and acts on ﬁ  broblasts to increase the 
transcription of ﬁ  bronectin and procollagen. It also 
inhibits synthesis of proteases and increases the 
synthesis of anti-proteases, thus resulting in a net 
increase in ﬁ  brosis. In a study to assess the role of 
TGF-β1 in the development of BPD, 40 preterm 
infants were enrolled. In this study, BPD was deﬁ  ned 
as oxygen dependency at 28 days with ‘radiographic 
changes.’ Eighteen infants developed BPD and had 
signiﬁ  cantly increased levels of TGF-β1 in tracheal 
aspirates, when compared to those with RDS and 
the controls.(51) TGF-β1 was also noted to be 
increased in one study assessing the levels of seven 
cytokines in ventilated babies in the ﬁ  rst 5 days of 
birth. Thirty-one preterm infants were enrolled, and 
tracheal aspirates taken until extubation to determine 
which levels of particular cytokines were abnormal 
in those with disease typical of “old” and “new” 
BPD. The eleven patients with both the old and new 370
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version of this disorder had elevated TGF-β1, 
though not statistically signiﬁ  cant.(22)
Tumor necrosis factor–α (TNF–α)
TNF-α is a proinﬂ  ammatory cytokine that induces 
cell death, and enhances expression of other 
cytokines. Jonsson and colleagues enrolled 28 
preterm infants, in a study to observe if early 
increased levels of proinflammatory cytokines 
predicted BPD. Their results showed TNF-α to be 
increased early in the seventeen patients who devel-
oped BPD.(27)
Peptide growth factors
Peptide growth factors are important for normal 
lung development, maturation and repair. Inclusive 
of this group are fibroblast growth factor-2, 
vascular endothelial growth factor, endothelin-1 
and keratinocyte growth factor.(52) Their speciﬁ  c 
roles are described below.
Endothelin-1
Endothelin-1 is a potent endothelium-derived 
vasoconstricting and bronchoconstricting factor, 
produced in virtually all tissues, though its largest 
concentration is in the lung. Under the inﬂ  uence of 
cytokines (IL-1β, IL-6, IL-8), production of 
endothelins can be induced in macrophages and 
monocytes.(53) Endothelin-1 has also been 
hypothesized to increase the production of oxygen 
radicals from alveolar macrophages. It was theo-
rized that in patients with BPD, that endothelin-1 
would be up-regulated, secondary to increased 
inﬂ  ammation. Thirty-four preterm infants with RDS 
were enrolled in a study to elucidate endothelin-1 
levels and its association with BPD. Half the infants 
eventually developed BPD and in the ﬁ  rst week of 
life it was noted that their endothelin-1 levels were 
signiﬁ  cantly elevated when compared to infants 
who did not later develop BPD.(54)
Fibroblast growth factor -2/basic 
ﬁ  broblast growth factor
(FGF2/bFGF)
FGF plays a role in angiogenesis, by stimulating 
endothelial cell proliferation, degrading extracellular 
matrix and appears to interact with vascular 
endothelial growth factor.(55) Thirty premature 
infants were studied to evaluate levels of peptide 
growth factors, including FGF-2 and the outcome 
of BPD. In this study, 18 developed BPD and/or 
died. There was a signiﬁ  cant elevation in the levels 
of FGF-2 in the BPD/death population on day 1 of 
life.(52)
Keratinocyte growth factor (KGF)
A member of the ﬁ  broblast growth factor family, 
KGF regulates proliferation of alveolar epithelial 
cells, enhances synthesis of surfactant and accel-
erates wound closure in airway epithelium. Danan 
and colleagues evaluated levels of KGF in pre-
mature infants at risk for BPD. Ninety-one pre-
mature infants were sampled before day 5, while 
still intubated. Fourteen infants developed BPD. 
It was noted that in those patients who developed 
BPD, KGF was lower than in those who did not 
develop it.(56)
Pulmonary hepatocyte growth factor 
(HGF)
HGF in fetal rat lungs stimulates branching of both 
alveolar and bronchial epithelia, and contributes 
to growth, maturation and maintenance of tissue 
homeostasis. It is suggested that HGF also medi-
ates repair of type II pneumocytes after acute lung 
injury. Thirty two preterm infants were evaluated 
for levels of HGF and correlation with develop-
ment of BPD. Seventeen out of 32 developed BPD 
and had signiﬁ  cantly lower levels of HGF in the 
ﬁ  rst 2 weeks of life, when compared to non-BPD 
counterparts.(57)
Vascular endothelial growth factor 
(VEGF)
VEGF promotes endothelial cell growth and remod-
eling. In the pulmonary system it appears to be 
essential for the appropriate development of alveo-
lar tissue; in rats its antagonism has been shown to 
result in dramatically impaired alveolarization, 
especially earlier in the course of lung develop-
ment.(58) In heavily vascularized tissues, such as 
the lung, VEGF exists in high concentrations. Dur-
ing hyperoxic episodes when damage to the 
microvasculature occurs, VEGF plays a role in the 
remodeling process, and its’ levels are increased, 
sometimes disproportionately. As such, it was 
hypothesized that in BPD, VEGF levels may 
correlate with severity. Lassus and colleagues 
enrolled 44 preterm infants with RDS in a study to 371
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characterize VEGF levels in tracheal aspirates and 
plasma. They found that the 13 infants developing 
BPD had signiﬁ  cantly lower levels of tracheal 
aspirate VEGF closer to one week of life.(59) No 
difference in tracheal aspirate VEGF levels were 
noted between BPD vs no BPD infants in the study 
by Ambalavanan et al.(52) In a recent study, a pha-
sic pattern of VEGF concentrations was noted in 
infants who go on to develop BPD. These infants 
had an initial spike over the ﬁ  rst 12 hours of post-
natal life, followed by a decrease over the next 
few days and then a subsequent significant 
increase.(60)
Summary
Bronchopulmonary dysplasia, a chronic respiratory 
disorder of very premature infants is one of the lead-
ing causes of mortality and morbidity in the neona-
tal intensive care unit. Currently there are many 
clinical associations predisposing to its’ develop-
ment. Alterations in a variety of pathways involved 
in normal lung development have been proposed in 
the mechanisms responsible for the pathologic 
changes we observe with BPD. Inﬂ  ammatory cells 
produce cytokines and chemoattractants for augmen-
tation of the inﬂ  ammatory response, in an attempt 
to curb the damage of the initial and potentially 
ongoing insults. Subsequent disruption of the 
alveolar capillary unit with increased vascular per-
meability, and decreased pulmonary tissue integrity 
occurs. The attempt at repair, differentiation and 
growth of these tissues act in concert with the inﬂ  am-
matory process to produce the biochemical markers, 
signs and symptoms observed in patients with, and 
those at risk for, BPD. As such, a variety of pulmo-
nary biomarkers that relate intimately to these 
pathways have been studied to see if they predict 
which neonates will go on to develop the disorder. 
The aberrancies noted in the pulmonary concentra-
tions of these biomarkers in preterm infants at risk 
for, or who have BPD, may one day be important 
for early diagnosis of the disorder. The limitations 
of the cited studies are the small sample size, and 
an inability to get biomarker concentrations in a 
control population of healthy, term infants. Currently, 
there is no one speciﬁ  c marker to predict development 
of BPD; thus we are limited to waiting for the 
clinical picture to take shape, often then managing 
its’ resultant morbidity and mortality. Perhaps there 
will ultimately be a panel of pulmonary biomarkers 
that indicate a strong predisposition prior to the 
clinical onset of BPD, or perhaps prior to its current 
time of diagnosis of  28 days postnatally or 36 weeks 
postmenstrually. This would allow us to be more 
targeted in our attempts at ﬁ  nding other therapies 
and modes of preventing this morbid sequela of 
prematurity.
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